CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant
CORAT antibody COR-101 recognizes the current “Indian” mutant B.1.617
CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment
CORAT Therapeutics secures additional funding
TV report on COR-101
CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients. The article can be viewed...
First hospitalized COVID-19 patient treated with the antibody drug candidate COR-101
Tübingen, Germany, 23.4.2021 – CORAT Therapeutics initiated a Phase Ib/II clinical trial evaluating the safety, tolerability, and efficacy of COR-101 in a total of 45 patients at five sites in Germany CORAT Therapeutics GmbH announced the start of a clinical...